VISTN Vistin Pharma ASA

Vistin Pharma ASA: Annual Report for 2019

Vistin Pharma ASA: Annual Report for 2019

Oslo, 23 April 2020

Please find attached the Annual Report for 2019 for Vistin Pharma ASA. There are no material changes in the financial statements compared to the preliminary full year results presented on 28 February 2020.

The annual report for 2019 will also be made available on .

*****

For further information, please contact:

Alexander Karlsen

CFO



Attachment

EN
23/04/2020

Underlying

VISTNVistin Pharma ASA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vistin Pharma ASA

 PRESS RELEASE
Free
VISTN Vistin Pharma A...

Vistin Pharma ASA (VISTN): Update from the Election Committee

Vistin Pharma ASA (VISTN): Update from the Election Committee Oslo, Norway, 07 May 2025 The Election Committee has received a request from Øystein Stray Spetalen that he does not want to be re-elected as a board member of Vistin Pharma ASA. The Election Committee has therefore assessed the consequences of this for the recommendation submitted 13 March 2025 to this year's annual general meeting. Øystein Spetalen was the only board member up for election, and it was recommended that he was re-elected. The composition of the board's expertise has been assessed, and it has been investigated w...

May 7, 2025 1 EN
 PRESS RELEASE
Free
VISTN Vistin Pharma A...

Vistin Pharma ASA (VISTN): Mandatory notification of trade and disclos...

Vistin Pharma ASA (VISTN): Mandatory notification of trade and disclosure of large shareholding Ferncliff Listed Dai AS has on 6 May 2025 sold 1,234,280 shares in Vistin Pharma ASA at NOK 22.50 per share. Saga Pure ASA has on 6 May 2025 sold 700,000 shares in Vistin Pharma ASA at NOK 22.50 per share. After the transaction Saga Pure ASA and Ferncliff Listed Dai AS has no holding of shares in Vistin Pharma ASA. Øystein Stray Spetalen and associated parties have a holding of 331,886 shares in Vistin Pharma ASA. Saga Pure ASA and Ferncliff Listed Dai AS are closely associated with board mem...

May 6, 2025 1 EN
 PRESS RELEASE
Free
VISTN Vistin Pharma A...

Vistin Pharma ASA: Notice of Annual General Meeting 22 May 2025

Vistin Pharma ASA: Notice of Annual General Meeting 22 May 2025 Oslo, Norway, 29 April 2025 Vistin Pharma ASA (OSE: VISTN), please find attached the call for the Annual General Meeting in Vistin Pharma, to be held on 22 May 2025 at 13:00 CEST. A physical Annual General Meeting will not be held. Instead, shareholders should authorize the Chairman of the Board. It is possible to give proxy with and without voting instructions. By using a proxy with voting instructions, the shareholders will vote on the specific issues without personal attendance. For further information on the use of prox...

April 29, 2025 1 EN
 PRESS RELEASE
Free
VISTN Vistin Pharma A...

2024 Annual Report Vistin Pharma ASA

2024 Annual Report Vistin Pharma ASA Oslo, Norway, 25 April 2025 Please find attached the Annual Report for 2024 for Vistin Pharma ASA (VISTN). There are no material changes in the financial statements compared to the preliminary full year results presented on 13 February 2025. The annual report for 2024 will also be made available on . ***** For further information, please contact: Alexander KarlsenCFO   This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.     Attachments ...

April 25, 2025 1 EN
 PRESS RELEASE
Free
VISTN Vistin Pharma A...

Vistin Pharma ASA: First quarter 2025 financial results

Vistin Pharma ASA: First quarter 2025 financial results Oslo, Norway, 25th of April 2025 Vistin Pharma ASA (VISTN) today announces the financial results for the first quarter of 2025. Revenue in the first quarter ended at MNOK 115 compared to MNOK 104 in Q1 2024. Sales volume in the quarter was up by 14% compared to same quarter last year. First quarter EBITDA ended at MNOK 30 compared to MNOK 20 in Q1 2024, an increase of 48%. EBITDA positively affected by increased sales volume and product mix in the quarter, in addition to continues focus on cost improvements. The net profit ended at...

April 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch